Brickell is a clinical-stage pharmaceutical company focused on the development of innovative and differentiated therapeutics for the treatment of skin diseases.

OUR RESEARCH

Pipeline
Our current pipeline consists of new molecular entities with relevant mechanisms of action in skin diseases, targeting significant market opportunities in the global dermatology market.

 

VIEW PIPELINE
Therapeutic Areas
Our current pipeline consists of new molecular entities targeting the treatment of the following indications:
  • Hyperhidrosis
  • Cutaneous T-cell Lymphoma
  • Allergic Contact Dermatitis
  • Psoriasis
  • Androgenic Alopecia

 

LEARN MORE
Brickell Outward Bound Leadership Retreat 2018

NEWS

News
June 3, 2019

Vical and Brickell Announce Merger Agreement 

Combined Company Well-Capitalized with Approximately $35 Million in Cash and up to $25 Million in Near-Term R&D Funding Pivotal Phase 3 Clinical Trials for Brickell’s Lead Product Candidate, Sofpironium Bromide,…
News
January 24, 2019

Brickell Featured in Denver Business Journal

News
November 19, 2018

Brickell Biotech Appoints Top Lilly Executive, Robert Brown, As Chief Executive Officer

Notable leadership change comes as Brickell prepares to progress its lead product candidate, sofpironium bromide, to Phase 3 clinical trials in primary axillary hyperhidrosis (excessive underarm sweating) BOULDER, CO, November…
ALL NEWS